BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Compugen Ltd. (CGEN) Announces Initial Validation Results for Two Novel Immunomodulatory Proteins and Further Results for CGEN-15001


4/24/2012 9:13:01 AM

TEL AVIV, Israel--(BUSINESS WIRE)--Compugen Ltd. (NASDAQ: CGEN) today reported the initial validation of two additional therapeutic product candidates, CGEN-15031 and CGEN-15051, in animal models of autoimmune diseases. These two novel molecules are soluble proteins based on two B7/CD28-like proteins discovered by Compugen, with each fusion protein combining the extracellular domain of one of the membrane proteins and an Fc antibody fragment. The results being announced today relate to the recently completed evaluation of the potential therapeutic activity of CGEN-15031 in an animal disease model of multiple sclerosis and of CGEN-15051 in a model of rheumatoid arthritis. The Compugen fusion proteins significantly ameliorated disease symptoms in these models and are predicted to have a potential use as protein therapeutics for multiple autoimmune diseases. The study of CGEN-15031 in the EAE model of multiple sclerosis was carried out in the laboratory of Prof. Stephen Miller at Northwestern University. CGEN-15051 was tested using the CIA model of rheumatoid arthritis at a commercial lab specializing in animal models of autoimmune diseases.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES